Goldfarb studies coherent effects in atomic vapours - EIT and slow light, spin-noise spectroscopy of spin-environment interaction, and EIT-based Rydberg-atom radio-frequency field sensing (electrometry) in warm cells. In the broader landscape of NV-centre ensemble quantum sensing (DEER, nano-NMR, T1 relaxometry) operating near pT/sqrt(Hz) sensitivity, this work adds atomic-vapour electrometry and coherence spectroscopy.

Uses single-molecule fluorescence microscopy in live bacteria to study stochastic gene expression, chromosome organization, and cell-to-cell variability.

Studies experimental quantum optics and atomic physics, including quantum light-matter interfaces, quantum memories, and single-photon sources based on atom-like emitters in solids, for applications in long-distance quantum communication and quantum networking.

Develops all-glass optical microresonator (microtoroid) platforms for label-free single-molecule and single-particle spectroscopy, extending single-molecule methods beyond fluorescent labels to study catalysis, protein folding, and photovoltaic materials.

Goldys was Deputy Director of the ARC Centre of Excellence for Nanoscale BioPhotonics and now leads a nanoscale biophotonics group in Biomedical Engineering. The programme is about extracting diagnostic information from very weak optical signals inside cells and tissue: luminescent and upconverting nanoparticle probes with long lifetimes that allow time-gated, background-free detection; hyperspectral unmixing of native cellular autofluorescence (NADH, FAD, porphyrins) as a completely label-free readout of cell state, which she has pushed toward clinical use in reproductive medicine and cancer; and nanoparticle-mediated therapy. Positioned against the established body of NV-ensemble quantum sensing work — DEER, nanoscale NMR and T1 relaxometry protocols operating at pT/sqrt(Hz) field sensitivity — time-gated luminescence and NV relaxometry are two solutions to the same problem — how to read a faint, specific signal out of an autofluorescent, optically hostile biological background — and her clinical translation experience is exactly the missing capability in most quantum-biosensing groups. Preferred attribute present: advanced/label-based imaging with a genuine human-application pathway.

Golwala's group develops ultrasensitive cryogenic detectors - phonon-mediated devices and kinetic-inductance/TES arrays - for direct dark-matter detection (SuperCDMS) and millimeter/submillimeter astrophysics and CMB measurements, working closely with JPL on detector technology. For context, this complements the established paradigm of NV-diamond ensemble magnetometry (Hahn-echo/DEER, nanoscale NMR, T1 relaxometry) operating near pT/√Hz sensitivity.

Gooding is one of the world's most-cited biosensor scientists (inaugural editor-in-chief of ACS Sensors) and runs a group of over thirty researchers spanning surface chemistry, electrochemistry and nanomedicine. The sensing programme that matters here is the move from ensemble to digital, single-molecule-resolved detection: nanoparticle-tethered electrochemical sensors in which single binding events are counted rather than averaged, nanopore blockade sensors for protein biomarkers such as PSA, amplification-free nucleic-acid detection, and antifouling surface chemistries that make any of this work in real biological fluid. He has a strong commercialisation record (AgaMatrix glucose sensors). Positioned against the established body of NV-ensemble quantum sensing work — DEER, nanoscale NMR and T1 relaxometry protocols operating at pT/sqrt(Hz) field sensitivity — his single-molecule-counting philosophy is the biosensing analogue of moving from a pT/sqrt(Hz) NV ensemble to single-spin detection: in both cases the sensitivity gain comes from resolving individual events rather than improving an averaged signal. He is also the obvious collaborator for anyone trying to functionalise a diamond or nanoparticle quantum sensor for a real analyte.

Gopinath's group develops photonic tools for sensing and imaging - electrowetting adaptive-optics and miniature two-photon/STED microscopes for in vivo neural imaging, dual-comb ranging and orbital-angular-momentum rotation sensing, and mid-infrared lasers/materials and fiber sensing. For context, this complements the established paradigm of NV-diamond ensemble magnetometry (Hahn-echo/DEER, nanoscale NMR, T1 relaxometry) operating near pT/√Hz sensitivity.

Gradinaru's group develops neurotechnologies - tissue clearing (CLARITY/PACT), engineered AAV gene-delivery vectors that cross the blood-brain barrier, optogenetic actuators/sensors, and light-sheet + single-molecule FISH imaging of cleared tissue - to map and manipulate neural circuits underlying neurodegeneration and behavior. For context, this complements the established paradigm of NV-diamond ensemble magnetometry (Hahn-echo/DEER, nanoscale NMR, T1 relaxometry) operating near pT/√Hz sensitivity.

Graham's group develops SERS-based nanoplasmonic sensing platforms for biomedical applications. Research directions: (1) SERS nanogap substrates — engineering colloidal gold and silver nanostructure clusters with reproducible, high-enhancement nanogaps for single-molecule SERS detection; (2) In vivo SERS — intravenous SERS nanotags for tumor imaging and multiplexed biomarker detection in living organisms; (3) Microfluidic SERS — integrating SERS probes in microfluidic channels for continuous monitoring of circulating biomarkers; (4) Quantitative SERS — calibration strategies for absolute analyte quantification for clinical diagnostics. Extreme sensitivity (single-molecule) relevant to quantum-enhanced optical sensing.